Company news

Fortuna Fix Announces the Appointment of Madhavan Balachandran to the Board of Directors; Jan-Eric Ahlfors, CEO of Fortuna Fix Inc., to present at IABS/CIRM 4th Cell Therapy Conference on June 6, 2018 in Los Angeles

Fortuna Fix is focusing on manufacturing and appoints Mr Balachandran to the Board of Directors. CEO Jan-Eric Ahlfors was invited to present at the 4th Stem Cell conference hosted by IABS and CIRM on manufacturing.

Continue reading →

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

LONDON AND MONTREAL, November 8, 2017 (Newswire.com) - Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”) to replace lost neuronal tissue in neurodegeneration and neurotrauma.

Continue reading →

Fortuna Fix Presenting at Unite to Cure: The Fourth International Vatican Conference — How Science, Technology and 21st Century Medicine Will Impact Culture and Society

LONDON, April 26, 2018 (Newswire.com) - Fortuna Fix Ltd (“Fortuna”), is a private regenerative medicine company aiming to be the first to bring to the clinic the patients' own (autologous) directly reprogrammed neural precursor cells (“drNPCs”) to replace lost neuronal tissue in neurodegeneration and neurotrauma. On Friday, April 27, 2018, Jan-Eric Ahlfors, CEO and CSO of Fortuna, will be presenting at the Fourth International Vatican Conference “Unite to Cure”. Fortuna’s directly reprogrammed cell technology platform will feature in a session entitled “The Pharmacy of the Future – Stem Cells and Cardiovascular, Pulmonary and Neurodegenerative Diseases”.

Continue reading →

Fortuna Fix annonce le financement de séries B, ajoutant Amgen Ventures et le gestionnaire de patrimoine Macnguyen parmi ses actionnaires

Londres, Royaume-Uni et Montréal, Canada, November 8, 2017 (Newswire.com) - ​​​​​​​​​​​​La société privée Fortuna Fix (“Fortuna”) basée au Centre Québécois d'Innovation en Biotechnologie (CQIB) et INRS-Institut Armand Frappier à Laval, se concentre sur la Médecine Régénérative et est plus précisément spécialisée dans la production de cellules souches neurales autologues (du patient lui-même) par reprogrammation cellulaire directe. Avec cette récente levée de fonds de 25 M$ US, Fortuna sera en mesure d’exécuter les phases I/IIa cliniques visant à établir le profil d'efficacité et d'innocuité de ses cellules souches autologues neurales reprogrammées (drNPCs), pour la maladie de Parkinsons et pour les lésions de la moelle épinière.

Continue reading →

Conference: Midwest Conference on Cell Therapy and Regenerative Medicine

Midwest Conference on Cell Therapy and Regenerative Medicine (September 2017, Kansas). This conference is a small targeted annual event for “ethical” stem cells, focusing on translational work and moving products to the clinics. The presentation was well received and opened significant dialogues with opinion leaders within the ethical stem cell environment.

Continue reading →

Conference: BioJapan World Business Forum

BioJapan World Business Forum (October, 2017, Yokohama) is the largest event in Japan and in Asia which provides open innovation interface for foreign biotech companies with Japanese large pharmaceutical companies. Fortuna Fix made an oral presentation. Japan is the birth of place of the iPS cells (induced pluripotent stem cells).

Continue reading →

Conference: Military Health System Research Symposium (MHSRS)

The MHSRS is the Department of Defense’s premier scientific meeting (Florida, August 2017). It provides a venue for presenting new scientific knowledge resulting from military-unique research and development. The MHSRS is the only military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter. Fortuna had 2 poster presentations.

Continue reading →

Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board

MONTREAL, May 4, 2017 /PRNewswire/ -- Fortuna Fix Inc. ("Fortuna"), a private, clinical-stage biotech company, is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat neurodegenerative diseases. Fortuna announced today the launch of its Scientific Advisory Board ("SAB") with Professor Michael Fehlings, MD, PhD; Father Kevin FitzGerald, S.J., PhD; Col. (R) Dallas Hack, MD, MPH; and Professor James Giordano, PhD.

Continue reading →